Cardiometabolic & kidneyResearch article
MASLD, MASH, and the cardiovascular, kidney, and metabolic (CKM) Spectrum
- Narrative review
Study context
- Population
- Individuals with cardiovascular, kidney and metabolic (CKM) disorders and MASLD/MASH
Main finding
As reported in the abstract
Evidence linking MASLD/MASH with CKM diseases (narrative review)
- MASLD is highly prevalent in individuals with CKM disorders, and vice versa
- Concomitant presence amplifies the risk of both CKM and liver-related outcomes
- Shared mechanisms: systemic inflammation, lipotoxicity and fibrotic remodeling
- Focus of HF, CKD and MASLD/MASH trials on single disease states has created knowledge gaps
Original publication
MASLD, MASH, and the CKM Spectrum. J Am Coll Cardiol. Published 4 February 2026. doi:10.1016/j.jacc.2025.12.015
Summarised from the published abstract; every number is checked against it